What Is Cartalax? Definition and What Research Reports

Plain definition

Cartalax is a name used for a very short synthetic peptide made of three amino acids — alanine, glutamic acid and aspartic acid — usually written with the single-letter code AED or as Ala-Glu-Asp. It belongs to a family of compounds often called "peptide bioregulators" or "Khavinson peptides," a group of two-, three- and four-amino-acid sequences that were originally isolated from animal tissue extracts and later reproduced synthetically. In non-academic sources the name Cartalax is usually attached to cartilage or connective tissue, because the bioregulator family is traditionally organised by the tissue the parent extract came from. That naming convention is a historical labelling system, not a description of a demonstrated clinical effect. This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about any compound.

What Cartalax is in biochemical terms

Chemically, AED is a tripeptide: three amino-acid residues joined by two peptide bonds, with a molecular size far smaller than hormones such as insulin or growth hormone. Two of its three residues (glutamic and aspartic acid) are acidic, which is a feature shared across much of the bioregulator family and is central to the mechanism its developers proposed.

That proposed mechanism is epigenetic rather than receptor-based. In a review of short-peptide biology, researchers described how peptides of two to four residues can enter cells and cell nuclei and interact with DNA and histone proteins, and they argued that such binding could modulate the transcription of particular genes (PMID 27909961). A related review framed the same family as epigenetic regulators involved in adaptive responses to pathology and ageing (PMID 33993656). These are mechanistic hypotheses supported mainly by cell and animal data, not by outcome trials in people.

Where the term came from

The bioregulator concept grew out of mid-to-late twentieth-century work on peptide–protein complexes extracted from animal organs. One structural study characterised a peptide–protein complex obtained from cattle sclera and reported chaperone-like activity in vitro, illustrating the kind of tissue-derived preparation that preceded the short synthetic sequences (PMID 33294633). An earlier paper set out the group's core organising idea — that peptides exert effects specific to the tissue from which the parent complex was obtained (PMID 11713572). Names like Cartalax, Vilon, Vesugen and Epitalon are product-style labels layered on top of that framework; the underlying peer-reviewed papers usually refer to the sequences themselves (AED, KE, KED, AEDG).

How the term is used in peptide research

In the scientific literature, the compound is far more often called AED or Ala-Glu-Asp than Cartalax. A direct example is a comparison study in which researchers examined the dipeptide KE and the tripeptide AED in cultures of human skin fibroblasts undergoing replicative ageing, and reported peptide-associated differences in markers of fibroblast functional activity between early and late passages (PMID 33231794). A separate fibroblast study in the same research tradition reported that short peptides influenced expression of proteins linked to proliferation and signalling in ageing skin fibroblast cultures (PMID 27259496).

Searchers looking for "cartalax" will therefore find that most of the retrievable primary literature is: (1) in vitro work on cultured human cells, (2) rodent models, and (3) reviews by the groups that developed the peptides. Independent replication outside those groups is limited.

Where the term is misused

• As a synonym for "joint treatment." The cartilage association comes from the tissue-origin naming system described above (PMID 11713572), not from cartilage outcome trials in the verified literature summarised here.
• As an approved drug. Cartalax is not an FDA-approved medicine in the United States. Material sold under the name is typically labelled research-use-only, which is a legal/labelling category rather than a statement about safety or efficacy.
• As interchangeable with Epitalon. Epitalon is the tetrapeptide AEDG, a different sequence with its own literature, including a review of its reported bioactivity (PMID 40141333) and a cell study on telomere length in stimulated human lymphocytes (PMID 31761987). Shared research lineage does not make the findings transferable.
• As a well-characterised human pharmacology. Human pharmacokinetic data — absorption, half-life, oral bioavailability — are not established in the papers cited on this page.

Related terms

What the published literature reports

Cell-culture and ageing models

The most directly relevant published work places AED in senescence models. In the comparison study, researchers assessed cultured human skin fibroblasts across replicative passages and reported that the two peptides differed in how they affected functional-activity markers in ageing cultures (PMID 33231794). Complementary work reported that short peptides modulated fibroblast function during in vitro ageing (PMID 27259496), and a stem-cell study reported protective effects of short peptides on ageing oral stem cell cultures (PMID 31677028).

Gene-expression framework

The mechanistic literature is where this family is discussed most. The review on short peptides and gene expression argued for direct peptide–DNA interaction as a route to transcriptional regulation (PMID 27909961), and a later review extended the framework to epigenetic adaptation during ageing and disease (PMID 33993656).

Animal models of other tripeptides

Several animal studies concern different sequences in the same family and are frequently — and incorrectly — cited as "Cartalax evidence." Researchers reported nephroprotective effects of the EDL peptide in rodent models of acute kidney injury (PMID 28744634), and a related paper reported restoration of kidney functional parameters in cisplatin-induced acute renal failure models (PMID 26515176). A separate study reported neuroprotective effects of tripeptide epigenetic regulators in a mouse model of Alzheimer's disease (PMID 34071923). These findings describe the compounds actually tested, not AED.

Safety and Adverse Events: What Studies Report

The verified literature summarised here is composed largely of in vitro experiments and animal models, and it does not include controlled human safety trials of AED. No human adverse-event profile, dose–response relationship or long-term safety dataset for Cartalax appears in the papers cited on this page. Reviews within the family describe reported bioactivity rather than systematic toxicology in people (PMID 40141333, PMID 33993656). The absence of reported harms in small laboratory studies is not evidence of human safety.

Limitations to keep in mind

• Much of the primary literature originates from a small number of affiliated research groups, limiting independent verification (PMID 11713572).
• Cell-culture results, such as those in fibroblast ageing models, do not translate automatically to whole organisms (PMID 33231794).
• Product-style names blur sequence differences; AED, KE, AEDG and EDL are distinct molecules with distinct datasets (PMID 31761987).

References

• Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging (Bulletin of Experimental Biology and Medicine, 2020)
• Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro (Bulletin of Experimental Biology and Medicine, 2016)
• Short Peptides Regulate Gene Expression (Bulletin of Experimental Biology and Medicine, 2016)
• Epigenetic regulation of adaptogenesis by pathology and aging (Advances in Gerontology, 2021)
• Short Peptides Protect Oral Stem Cells from Ageing (Stem Cell Reviews and Reports, 2020)
• Tissue-specific effects of peptides (Bulletin of Experimental Biology and Medicine, 2001)
• Peptide-protein complex from cattle sclera: Structural aspects and chaperone activity (Biochemistry and Biophysics Reports, 2020)
• Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties (International Journal of Molecular Sciences, 2025)
• Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes (Bulletin of Experimental Biology and Medicine, 2019)
• Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis (Bulletin of Experimental Biology and Medicine, 2017)
• Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure (Bulletin of Experimental Biology and Medicine, 2015)
• Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer's Disease (Pharmaceuticals, 2021)